That is on the forward work plan for NACI. The committee is currently reviewing evidence on interchangeability across vaccine platforms. As Dr. Tam mentioned, we expect some of that evidence to become available later in the month or into early June. There has already been some news released from a Spanish study looking at the same.
The committee is reviewing the scientific evidence on this topic in order to provide that advice on interchangeability. The Public Health Agency of Canada does intend to ask NACI for their advice about options for individuals who have received AstraZeneca as a first dose and whether interchangeability might be an option.
Thank you.